Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Michelle Ojemuyiwa, Karen Zeman, Alexander Spira, Bryan Oronsky, Carolyn Ray, Jane B. Trepel, Min Jung Lee, Ifeyinwa Onyiuke, Christina Brzezniak

Research output: Contribution to journalArticle

Abstract

Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

Original languageEnglish (US)
JournalClinical Case Reports
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Keywords

  • macrophage repolarization
  • neuroendocrine cancer
  • platinum doublets
  • priming
  • prostate cancer
  • RRx-001

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets'. Together they form a unique fingerprint.

  • Cite this